Laboratoires SERB (Charterhouse-backed) to acquire BTG Specialty Pharmaceuticals from Boston Scientific

December 1, 2020

Charterhouse Capital Partners–backed Laboratoires SERB has agreed to acquire BTG Specialty Pharmaceuticals from Boston Scientific. The deal expands SERB’s portfolio of emergency and critical‑care medicines (including CroFab, DigiFab and Voraxaze), strengthening its manufacturing capabilities and global commercial reach.

Buyers
Laboratoires SERB, Charterhouse Capital Partners LLP
Targets
BTG Specialty Pharmaceuticals
Sellers
Boston Scientific
Platforms
Laboratoires SERB
Industry
Pharmaceuticals
Location
Pennsylvania, United States
Transaction Type
Addon

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.